Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/13/5/756 |
| _version_ | 1827694148393631744 |
|---|---|
| author | Johannes Korth Michael Jahn Oliver Dorsch Olympia Evdoxia Anastasiou Burkhard Sorge-Hädicke Ute Eisenberger Anja Gäckler Ulf Dittmer Oliver Witzke Benjamin Wilde Sebastian Dolff Andreas Kribben |
| author_facet | Johannes Korth Michael Jahn Oliver Dorsch Olympia Evdoxia Anastasiou Burkhard Sorge-Hädicke Ute Eisenberger Anja Gäckler Ulf Dittmer Oliver Witzke Benjamin Wilde Sebastian Dolff Andreas Kribben |
| author_sort | Johannes Korth |
| collection | DOAJ |
| description | The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination. We investigated the SARS-CoV-2 immune response via SARS-CoV-2 IgG detection in 23 renal transplant recipients after two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol. The antibody response was evaluated once with an anti-SARS-CoV-2 IgG CLIA 15.8 +/− 3.0 days after the second dose. As a control, SARS-CoV-2 IgG was determined in 23 healthcare workers (HCW) and compared to the patient cohort. Only 5 of 23 (22%) renal transplant recipients were tested positive for SARS-CoV-2 IgG antibodies after the second dose of vaccine. In contrast, all 23 (100%) HCWs were tested positive for antibodies after the second dose. Thus, the humoral response of renal transplant recipients after two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech, Kronach, Germany) is impaired and significantly lower compared to healthy controls (22% vs. 100%; <i>p</i> = 0.0001). Individual vaccination strategies might be beneficial in these vulnerable patients. |
| first_indexed | 2024-03-10T11:59:09Z |
| format | Article |
| id | doaj.art-a2410822cc6446e1851983cdb2140601 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-10T11:59:09Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-a2410822cc6446e1851983cdb21406012023-11-21T17:06:35ZengMDPI AGViruses1999-49152021-04-0113575610.3390/v13050756Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)Johannes Korth0Michael Jahn1Oliver Dorsch2Olympia Evdoxia Anastasiou3Burkhard Sorge-Hädicke4Ute Eisenberger5Anja Gäckler6Ulf Dittmer7Oliver Witzke8Benjamin Wilde9Sebastian Dolff10Andreas Kribben11Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyDepartment of Nephrology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyKfH Kuratorium für Dialyse und Nierentransplantation e.V, KfH-Nierenzentrum Friesener Straße 37a, 96317 Kronach, GermanyInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstr. 179, 45147 Essen, GermanyKfH Kuratorium für Dialyse und Nierentransplantation e.V, KfH-Nierenzentrum Alfried-Krupp-Str. 43, 45131 Essen, GermanyDepartment of Nephrology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyDepartment of Nephrology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstr. 179, 45147 Essen, GermanyDepartment of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyDepartment of Nephrology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyDepartment of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyDepartment of Nephrology, University Hospital Essen, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, GermanyThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. Therefore, the effect of established messenger RNA (mRNA)-based SARS-CoV-2 vaccines have to be evaluated for solid organ transplant patients (SOT) since they are known to have poor responses after vaccination. We investigated the SARS-CoV-2 immune response via SARS-CoV-2 IgG detection in 23 renal transplant recipients after two doses of the mRNA-based SARS-CoV-2 vaccine BNT162b2 following the standard protocol. The antibody response was evaluated once with an anti-SARS-CoV-2 IgG CLIA 15.8 +/− 3.0 days after the second dose. As a control, SARS-CoV-2 IgG was determined in 23 healthcare workers (HCW) and compared to the patient cohort. Only 5 of 23 (22%) renal transplant recipients were tested positive for SARS-CoV-2 IgG antibodies after the second dose of vaccine. In contrast, all 23 (100%) HCWs were tested positive for antibodies after the second dose. Thus, the humoral response of renal transplant recipients after two doses of the mRNA-based vaccine BNT162b2 (Pfizer-BioNTech, Kronach, Germany) is impaired and significantly lower compared to healthy controls (22% vs. 100%; <i>p</i> = 0.0001). Individual vaccination strategies might be beneficial in these vulnerable patients.https://www.mdpi.com/1999-4915/13/5/756SARS-Cov-2 vaccinationrenal transplant recipientsrenal transplantationCOVID-19 |
| spellingShingle | Johannes Korth Michael Jahn Oliver Dorsch Olympia Evdoxia Anastasiou Burkhard Sorge-Hädicke Ute Eisenberger Anja Gäckler Ulf Dittmer Oliver Witzke Benjamin Wilde Sebastian Dolff Andreas Kribben Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) Viruses SARS-Cov-2 vaccination renal transplant recipients renal transplantation COVID-19 |
| title | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
| title_full | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
| title_fullStr | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
| title_full_unstemmed | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
| title_short | Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech) |
| title_sort | impaired humoral response in renal transplant recipients to sars cov 2 vaccination with bnt162b2 pfizer biontech |
| topic | SARS-Cov-2 vaccination renal transplant recipients renal transplantation COVID-19 |
| url | https://www.mdpi.com/1999-4915/13/5/756 |
| work_keys_str_mv | AT johanneskorth impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT michaeljahn impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT oliverdorsch impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT olympiaevdoxiaanastasiou impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT burkhardsorgehadicke impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT uteeisenberger impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT anjagackler impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT ulfdittmer impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT oliverwitzke impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT benjaminwilde impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT sebastiandolff impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech AT andreaskribben impairedhumoralresponseinrenaltransplantrecipientstosarscov2vaccinationwithbnt162b2pfizerbiontech |